Skip to content

Study · Animal study (in vivo) · c57bl and 6 mouse · 2013

5 results

Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury.

Hirata Y, Kurobe H, Nishio C, Tanaka K, Fukuda D, Uematsu E, Nishimoto S, Soeki T, Harada N, Sakaue H, Kitagawa T, Shimabukuro M, Nakaya Y, Sata M

European journal of pharmacology7 Dec 2012Cited by 47 (Europe PMC)

PMID23220706 (opens in a new tab)DOI10.1016/j.ejphar.2012.11.057 (opens in a new tab)PepBankPUB-23220706
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with vascular injury, exendin‑4 attenuated neointimal hyperplasia four weeks after injury.

    In plain wordsIn mice with artery injury, exendin‑4 reduced thickening of the artery's inner layer.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseNeointimal hyperplasia
    Study

    C57BL/6 mousen: not reported in source

    Wire-mediated femoral artery injury
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    24 nmol/kg/day · infusion pump · 4 weeksAs given in this study (C57BL/6 mouse).

    Source sentences

    Summary
    Four weeks after the injury, exendin-4 treatment significantly attenuated neointimal hyperplasia of the injured artery, although it did not affect glucose metabolism and lipid profile in wild-type mice.
    1 context sentence
    Summary · context
    We performed wire-mediated endovascular injury in C57BL/6 mice, followed by administration of exendin-4 24 nmol/kg/day via infusion pump.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In wild-type mice with vascular injury, exendin‑4 did not affect glucose metabolism.

    In plain wordsIn mice with artery injury, exendin‑4 did not change glucose metabolism.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeGlucose metabolism
    Study

    C57BL/6 mousen: not reported in source

    Wire-mediated femoral artery injury
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    24 nmol/kg/day · infusion pump · 4 weeksAs given in this study (C57BL/6 mouse).

    Source sentences

    Summary
    Four weeks after the injury, exendin-4 treatment significantly attenuated neointimal hyperplasia of the injured artery, although it did not affect glucose metabolism and lipid profile in wild-type mice.
    1 context sentence
    Summary · context
    We performed wire-mediated endovascular injury in C57BL/6 mice, followed by administration of exendin-4 24 nmol/kg/day via infusion pump.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In wild-type mice with vascular injury, exendin‑4 did not affect the lipid profile.

    In plain wordsIn mice with artery injury, exendin‑4 did not change the lipid profile.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeLipid profile
    Study

    C57BL/6 mousen: not reported in source

    Wire-mediated femoral artery injury
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    24 nmol/kg/day · infusion pump · 4 weeksAs given in this study (C57BL/6 mouse).

    Source sentences

    Summary
    Four weeks after the injury, exendin-4 treatment significantly attenuated neointimal hyperplasia of the injured artery, although it did not affect glucose metabolism and lipid profile in wild-type mice.
    1 context sentence
    Summary · context
    We performed wire-mediated endovascular injury in C57BL/6 mice, followed by administration of exendin-4 24 nmol/kg/day via infusion pump.
  4. 04LabIn vitro (cells)Mechanism

    In rat aortic smooth muscle cells, exendin‑4 reduced PDGF-BB-induced proliferation through the cAMP/PKA pathway.

    In plain wordsIn cells from rat arteries, exendin‑4 reduced growth stimulated by PDGF-BB through the reported signaling pathway.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseSmooth muscle cell proliferation
    Study

    ratn: not reported in source

    Rat aortic smooth muscle cells
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Cell proliferation assay using rat aortic smooth muscle cells showed that exendin-4 reduced PDGF-BB induced smooth muscle cell proliferation through the cAMP/PKA pathway.
  5. 05LabIn vitro (cells)Mechanism

    In peritoneal macrophages, exendin‑4 inhibited TNFα production in response to an inflammatory stimulus.

    In plain wordsIn cells, exendin‑4 reduced TNFα production after an inflammatory stimulus.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseTNFα production
    Study

    n: not reported in source

    Peritoneal macrophages
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exendin-4 also inhibited TNFα production by peritoneal macrophages in response to inflammatory stimulus.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.